Tafalgie Therapeutics expands R&D capabilities and moves into new premises

Tafalgie Therapeutics, a biopharmaceutical research company specialised in the development of treatments capable of relieving and preventing the onset of acute and chronic pain (inflammatory, post-operative, neuropathic) without side effects, announces that its teams are moving today to its new site in Luminy, Marseille, France, dedicated to research and support functions.

Tafalgie has chosen to establish its headquarters within the Marseille-Luminy Technology Park (CCIMP Building), allowing the company to be in the vicinity of both its main partner labs (IBDM, AFMB) and the Marseille University Hospital (AP-HM). This facility enables all teams to be grouped together on a single site with a surface area of almost 300 m2, with well-design collaborative workspace to support its growth and welcome its new employees in the best possible conditions.

Tafalgie Therapeutics will be able to accelerate all its development projects while improving the working environment and conditions for its employees.

Visit our contact page